Axogen Reports Q4 Revenue of $59.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy AXGN?
Reports Q4 revenue $59.9M, consensus $59.9M. "2025 was a remarkable year of financial and operational achievement for Axogen, as we attained or progressed every objective expected of our strategic plan. With the FDA's approval of our Biologics License Application for Avance as the only implantable biologic indicated for treatment of peripheral nerve discontinuities, and the continued demonstration of the effectiveness and predictability of our market development strategies, we are confident we have a foundation for future growth and advancement of our mission to make restoration of peripheral function a standard of care," commented Michael Dale, President and CEO of Axogen, Inc. "Importantly for shareholders, we exited 2025 financially stronger and positioned to continue our important work profitably while generating positive cash flow."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXGN
Wall Street analysts forecast AXGN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.640
Low
39.00
Averages
39.80
High
40.00
Current: 32.640
Low
39.00
Averages
39.80
High
40.00
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
DAFNA Capital Management Reduces Axogen Holdings
- Share Reduction: DAFNA Capital Management cut its Axogen holdings by 265,456 shares in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategy focused on portfolio balance after a 70% stock price increase.
- Holding Status: At the end of the quarter, DAFNA retained 476,826 shares of Axogen, valued at $15.61 million, representing 3.63% of its 13F reportable assets, highlighting the company's significance in its investment portfolio.
- Market Performance: Axogen's stock price surged 71% over the past year to $30.78, significantly outperforming the S&P 500's approximate 15% increase during the same period, reflecting strong growth potential in the peripheral nerve repair market.
- Financial Overview: With a market capitalization of $1.6 billion and TTM revenue of $225.2 million, Axogen reported a net loss of $15.7 million; however, the company achieved approximately 20% revenue growth in its core surgical markets, indicating ongoing double-digit expansion potential.
See More
Axogen Reports Q4 2025 Earnings with Strong Growth and FDA Milestone
- Financial Performance Growth: Axogen reported Q4 2025 revenue of $59.9 million, reflecting a 21.3% year-over-year increase, with full-year revenue reaching $225.2 million, demonstrating strong double-digit growth across all target markets and laying a solid foundation for sustainable future growth.
- FDA Approval Milestone: The company achieved a historic milestone with the FDA approval of the biologics license application (BLA) for Avance, granting 12 years of market exclusivity and establishing its standard position in nerve repair, which is expected to drive future market expansion.
- Capital Structure Optimization: Axogen completed an upsized public offering raising $133.3 million, using $69.7 million to retire its term loan, significantly improving its capital structure and enhancing financial flexibility to support future investments.
- Market Expansion Plans: The company plans to further expand its sales team in 2026, particularly in the Breast and Extremities markets, with expectations to grow the Breast team to 30 sales representatives and the Extremities team to 130, indicating a proactive approach to capturing market opportunities.
See More
HighMark Wealth Management Increases Axogen Stake to 4.6%
- Increased Holdings: HighMark Wealth Management LLC disclosed a purchase of 158,855 shares in Axogen (AXGN) in its fourth-quarter 13F filing, valued at approximately $4 million, raising its total stake to $11.2 million, an increase of $7.9 million, indicating strong confidence in the company.
- Market Performance: As of February 4, 2026, Axogen's stock traded at $34.22, reflecting an impressive 89.3% increase over the past year, significantly outperforming the S&P 500 by 75.3 percentage points, showcasing market recognition of its growth potential.
- Financial Status: Axogen reported trailing twelve-month revenue of $225 million, with a net loss of $15 million; however, its five-year compound annual growth rate stands at 11.9%, indicating stability in revenue growth.
- Product Innovation: Axogen specializes in surgical solutions for peripheral nerve repair and recently received FDA approval for Avance, further solidifying its competitive position in the medical device sector and expected to enhance future profitability.
See More
HighMark Wealth Management Increases Axogen Stake to 4.6% of AUM
- Share Increase: HighMark Wealth Management LLC added 158,855 shares of Axogen in Q4, bringing its total holdings to 343,940 shares valued at $11.2 million, demonstrating strong confidence in the company.
- Asset Proportion Growth: Axogen now accounts for 4.6% of HighMark's assets under management, positioning it among the fund's top five holdings, reflecting its significance and potential for growth within the investment portfolio.
- FDA Approval Boost: Axogen received FDA approval for its main product, Avance, in Q4, driving a 20% revenue increase to $225 million in 2024, which enhances confidence in its future profitability potential.
- Market Competitiveness: Axogen focuses on innovative surgical solutions for peripheral nerve injuries, leveraging proprietary biologic and extracellular matrix technologies to improve clinical outcomes, thereby strengthening its competitive position in the medical device sector.
See More
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
DAFNA Capital Management Reduces Axogen Holdings
- Share Reduction: DAFNA Capital Management cut its Axogen holdings by 265,456 shares in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategy focused on portfolio balance after a 70% stock price increase.
- Holding Status: At the end of the quarter, DAFNA retained 476,826 shares of Axogen, valued at $15.61 million, representing 3.63% of its 13F reportable assets, highlighting the company's significance in its investment portfolio.
- Market Performance: Axogen's stock price surged 71% over the past year to $30.78, significantly outperforming the S&P 500's approximate 15% increase during the same period, reflecting strong growth potential in the peripheral nerve repair market.
- Financial Overview: With a market capitalization of $1.6 billion and TTM revenue of $225.2 million, Axogen reported a net loss of $15.7 million; however, the company achieved approximately 20% revenue growth in its core surgical markets, indicating ongoing double-digit expansion potential.
See More
Axogen Reports Q4 2025 Earnings with Strong Growth and FDA Milestone
- Financial Performance Growth: Axogen reported Q4 2025 revenue of $59.9 million, reflecting a 21.3% year-over-year increase, with full-year revenue reaching $225.2 million, demonstrating strong double-digit growth across all target markets and laying a solid foundation for sustainable future growth.
- FDA Approval Milestone: The company achieved a historic milestone with the FDA approval of the biologics license application (BLA) for Avance, granting 12 years of market exclusivity and establishing its standard position in nerve repair, which is expected to drive future market expansion.
- Capital Structure Optimization: Axogen completed an upsized public offering raising $133.3 million, using $69.7 million to retire its term loan, significantly improving its capital structure and enhancing financial flexibility to support future investments.
- Market Expansion Plans: The company plans to further expand its sales team in 2026, particularly in the Breast and Extremities markets, with expectations to grow the Breast team to 30 sales representatives and the Extremities team to 130, indicating a proactive approach to capturing market opportunities.
See More
HighMark Wealth Management Increases Axogen Stake to 4.6%
- Increased Holdings: HighMark Wealth Management LLC disclosed a purchase of 158,855 shares in Axogen (AXGN) in its fourth-quarter 13F filing, valued at approximately $4 million, raising its total stake to $11.2 million, an increase of $7.9 million, indicating strong confidence in the company.
- Market Performance: As of February 4, 2026, Axogen's stock traded at $34.22, reflecting an impressive 89.3% increase over the past year, significantly outperforming the S&P 500 by 75.3 percentage points, showcasing market recognition of its growth potential.
- Financial Status: Axogen reported trailing twelve-month revenue of $225 million, with a net loss of $15 million; however, its five-year compound annual growth rate stands at 11.9%, indicating stability in revenue growth.
- Product Innovation: Axogen specializes in surgical solutions for peripheral nerve repair and recently received FDA approval for Avance, further solidifying its competitive position in the medical device sector and expected to enhance future profitability.
See More
HighMark Wealth Management Increases Axogen Stake to 4.6% of AUM
- Share Increase: HighMark Wealth Management LLC added 158,855 shares of Axogen in Q4, bringing its total holdings to 343,940 shares valued at $11.2 million, demonstrating strong confidence in the company.
- Asset Proportion Growth: Axogen now accounts for 4.6% of HighMark's assets under management, positioning it among the fund's top five holdings, reflecting its significance and potential for growth within the investment portfolio.
- FDA Approval Boost: Axogen received FDA approval for its main product, Avance, in Q4, driving a 20% revenue increase to $225 million in 2024, which enhances confidence in its future profitability potential.
- Market Competitiveness: Axogen focuses on innovative surgical solutions for peripheral nerve injuries, leveraging proprietary biologic and extracellular matrix technologies to improve clinical outcomes, thereby strengthening its competitive position in the medical device sector.
See More
